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Abstract
Background: The inactivation of tumor suppressor genes (TSGs) by aberrant DNA methylation plays an
important role in the development of malignancy. Since this epigenetic change is reversible, it is a potential
target for chemotherapeutic intervention using an inhibitor of DNA methylation, such as 5-aza-2'-
deoxycytidine (DAC). Although clinical studies show that DAC has activity against hematological
malignancies, the optimal dose-schedule of this epigenetic agent still needs to be established.
Methods: Clonogenic assays were performed on leukemic and tumor cell lines to evaluate the in vitro
antineoplastic activity of DAC. The reactivation of TSGs and inhibition of DNA methylation by DAC were
investigated by reverse transcriptase-PCR and Line-1 assays. The in vivo antineoplastic activity of DAC
administered as an i.v. infusion was evaluated in mice with murine L1210 leukemia by measurement of
survival time, and in mice bearing murine EMT6 mammary tumor by excision of tumor after chemotherapy
for an in vitro clonogenic assay.
Results: Increasing the DAC concentration and duration of exposure produced a greater loss of
clonogenicity for both human leukemic and tumor cell lines. The reactivation of the TSGs (p57KIP2 in HL-
60 leukemic cells and p16CDKN2A in Calu-6 lung carcinoma cells) and the inhibition of global DNA
methylation in HL-60 leukemic cells increased with DAC concentration. In mice with L1210 leukemia and
in mice bearing EMT6 tumors, the antineoplastic action of DAC also increased with the dose. The plasma
level of DAC that produced a very potent antineoplastic effect in mice with leukemia or solid tumors was
> 200 ng/ml (> 1 µM).
Conclusion: We have shown that intensification of the DAC dose markedly increased its antineoplastic
activity in mouse models of cancer. Our data also show that there is a good correlation between the
concentrations of DAC that reduce in vitro clonogenicity, reactivate TSGs and inhibit DNA methylation.
These results suggest that the antineoplastic action of DAC is related to its epigenetic action. Our
observations provide a strong rationale to perform clinical trials using dose intensification of DAC to
maximize the chemotherapeutic potential of this epigenetic agent in patients with cancer.
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The inactivation of tumor suppressor genes (TSGs) by epi-
genetic events, such as aberrant DNA methylation, plays
an important role in oncogenesis [1,2]. Since epigenetic
changes are reversible, they are promising targets for
chemotherapy using agents that inhibit DNA methylation
[3,4]. 5-Aza-2'-deoxycytidine (decitabine, dacogen, DAC)
is a potent demethylating agent [5], that has been shown
to reactivate TSGs [3] silenced by promoter DNA methyl-
ation [1,2]. In preclinical studies DAC was shown to have
potent antileukemic activity in the mouse model [6-8]. In
addition DAC showed potent antitumor activity against a
human tumor xenograft [9]. Its mechanism of action is
related to the induction of terminal differentiation, senes-
cence or apoptosis, resulting in an irreversible loss of pro-
liferative potential [10-12].
Clinical trials in patients with hematological malignan-
cies have shown that both low and intermediate doses of
DAC can produce responses [13-18]. In patients with
solid tumors, low dose DAC produced low response rates
[19-21], whereas in a pilot study high doses showed
promising activity [22]. Indeed, the dose-schedules of
DAC used in the clinical studies were very different, and it
appears that the optimal dose still needs to be refined in
order to fully exploit its chemotherapeutic potential.
In order to clarify the dose-schedule of DAC as a guide to
clinical trials, we have evaluated the antineoplastic activ-
ity of DAC both in vitro and in animal models. We have
observed that DAC reduced the in vitro clonogenic poten-
tial in a dose-dependent manner of both human and
murine leukemia and tumor cell lines. The in vitro antine-
oplastic action of DAC correlated well with its inhibition
of DNA methylation and reactivation of TSG in human
neoplastic cells. We also observed a correlation between in
vitro and in vivo concentrations needed to produce opti-
mal responses in mice with L1210 leukemia or with EMT6
tumor. These observations may be useful in the design of
optimized dose-schedules of DAC for future clinical trials




DAC (molecular weight 228.2) was obtained from A. Pis-
kala, Institut of Organic Chemistry and Biochemistry,
Czechoslovak Academy of Science, Prague, Czeckoslova-
kia. DAC was dissolved in sterile phosphate buffer saline
pH 6.8 (PBS) solution and stored at -70°C to prevent
decomposition.
Cell culture
The mouse lymphoid leukemia cell line L1210 was
obtained from Dr. T. Khwaja (University of Southern Cal-
ifornia, Los Angeles). These cells were maintained in
RPMI-1640 medium (Canadian Life Technologies, Burl-
ington, Ontario) with 5% heat-inactivated fetal calf serum
(WISENT, St-Bruno, Quebec) and with 6 µM of 2-mercap-
toethanol. The mouse mammary tumor cell line EMT6
was obtained from spontaneous mammary tumor of
BALB/c mouse [23]. These cells were maintained in MEM
F-14 medium (Canadian Life Technologies) with 10%
heat-inactivated fetal calf serum and with 25 units/ml of
penicillin, 25 µg/ml of streptomycin and 0.1 mg/ml of
calcium chloride. The doubling time of both murine cell
lines was ~12 h. The human acute promyelocytic leuke-
mic cells HL-60 (ATCC, USA) and the lung carcinoma
cells Calu-6 were maintained in RPMI-1640 medium
(Canadian Life Thecnologies) with 10% heat-inactivated
foetal calf serum (WISENT). The doubling times of the
HL-60 and Calu-6 cells were 16 and 30 h, respectively. All
cells lines were maintained at 37°C with 5% CO2.
Clonogenic assays
A 5 ml aliquot of HL-60 or L1210 (104 cells/ml) in log
growth phase were placed in 25 cm2 tissue-culture flasks.
The indicated concentrations of DAC were added. The
flasks were incubated at 37°C and at the indicated times,
an aliquot was removed for counting with a Model Z
Coulter Counter. An aliquot of 100 cells was placed in 2
ml of 0.3% soft agar RPMI 1640 medium containing 20%
serum for HL-60 (Table 1) or 10% serum plus 6 µM 2-
mercaptoethanol (Sigma) for L1210 cells (Table 3). For
EMT6 tumor, 5 ml (200 cells) were placed in a Petri dish
Table 1: Effect of different concentrations and exposure times of DAC on loss of clonogenicity of human HL-60 myeloid leukemic 
cells.
Loss of clonogenicity (%)
DAC Concentration ng/ml (µM) Exposure time
2 h 6 h 24 h 48 h
10 (0.044) 11.8 ± 9.8a 43.9 ± 10.2a 44.9 ± 15.9a 69.0 ± 19.9a
20 (0.088) ND ND 56.1 ± 19.2 ND
100 (0.44) 43.9 ± 7.8 74.0 ± 9.8 83.9 ± 4.9 99.7 ± 0.8
200 (0.88) 56.4 ± 14.8 77.2 ± 10.7 99.2 ± 2.1 100
1,000 (4.4) 61.3 ± 14.7 89.3 ± 3.8 ND 100
aMean values ± S.D., n ≥ 4Page 2 of 10
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were then added for 18 h exposure (Table 3). The drug was
removed and the cells were placed in drug-free medium.
For Calu-6 lung carcinoma cells, 2 ml (100 cells) were
plated in 6-well dishes and incubated for 24 h prior to
addition of different concentrations of DAC (Table 2).
The drug was removed after the different exposure times
and the cells were placed in drug-free medium. The
number of colonies (> 500 cells) was counted after 7 days
of incubation for both L1210 and EMT6 cells (Table 3),
and after 14 days of incubation for HL-60 (Table 1) and
Calu-6 cells (Table 2). The cloning efficiency of all the
cells was in the range of 60–75%.
Isolation of RNA and RT-PCR
In order to study the epigenetic effect of DAC, the reacti-
vation of the tumor suppressor genes p57CDKN1C (p57)
(GenBank accession number NM_000076) [8] on HL-60
cells and p16CDKN2A (p16) (GenBank accession
number NM_058197) [24] on Calu-6 cells was evaluated.
HL-60 leukemic cells and Calu-6 lung carcinoma cells
were treated with different concentrations of DAC for 48
h (Fig. 1). Total RNA was isolated 24 h after drug removal
using RNeasy Mini Kit (Qiagen, Mississauga, Ontario,
CA). For cDNA synthesis, RNA was reverse-transcribed as
previously described [8]. PCR amplifications were per-
formed using HotStar Taq Polymerase (Qiagen) and spe-
cific primers spanning different exons for human 18S
ribosomal RNA (18S) (Gen Bank accession number
X03205) [8], p57 [8] and p16 [25]. The 18S was amplified
as an internal control. Samples were amplified in a What-
man Biometra T gradient thermocycler (Göttingen, Ger-
many) under the following conditions (previously
described for 18S and p57 [8]). For p16, 15 min at 95°C
to activate Taq polymerase, denaturation at 94°C for 45 s,
annealing at 59°C for 30 s and extension at 72°C for 30
s, for 5 cycles. Then, the annealing temperature was low-
ered by 2°C for an additional 35 cycles. The length or the
PCR products were 110, 167 and 117 bp for 18S, p57 and
p16 respectively. For each gene, the number of cycles was
determined during the exponential phase of DNA ampli-
fication. The PCR products were electrophoresed on 2%
agarose gel and detected by ethidium bromide staining.
For quantitative detection of gene expression, we used the
18S as the reference standard to normalize the data. The
concentration of the amplified DNA was determined by
Agilent 2100 Bioanalyzer (Palo Alto, CA). This instrument
uses a very sensitive capillary electrophoresis and fluores-
cent detection to measure the concentration and size of
DNA from a sample size of only 1 µl (Fig. 1B and 1C).
Isolation of DNA and bisulfite treatment
In order to study the global methylation status of the
genome of the HL-60 leukemic cells, the LINE-1 (Gen-
Bank accession number AF148856) assay was used [26].
The specific methylation status of the promoter of the p57
gene (GenBank accession number NC_000011) has also
been studied in these cells. HL-60 cells were treated with
different concentrations of DAC (10, 100 and 1000 ng/ml
or 0.044, 0.44 and 4.4 µM) for 48 h. Genomic DNA was
Table 2: Effect of different concentrations and exposure times of DAC on loss of clonogenicity of human Calu-6 lung carcinoma cells.
Loss of clonogenicity (%)
DAC Concentration ng/ml (µM) Exposure time
4 h 8 h 24 h 48 h
1 (0.0044) ND ND 16.4 ± 9.1a 10.3 ± 5.9a
10 (0.044) 25.5 ± 15.6a 20.1 ± 15.2a 30.7 ± 11.4 22.5 ± 19.4
100 (0.44) 59.8 ± 20.2 71.1 ± 9.3 83.9 ± 14.2 71.6 ± 11.1
1,000 (4.4) 82.4 ± 10.2 83.4 ± 1.1 98.0 ± 4.2 100 ± 0
aMean values ± S.D., n ≥ 3
Table 3: Effect of different concentrations of DAC on loss of clonogenicity by L1210 murine lymphoblastic leukemia, or by EMT6 
murine mammary tumor cellsa
DAC Concentration ng/ml (µM) L1210 Loss of clonogenicity (%) EMT6 Loss of clonogenicity (%)
1 (0.0044) 25.3 ± 12.4b -
10 (0,044) 41.4 ± 8.8 12.3 ± 5.5b
100 (0.44) 98.6 ± 1.3 69.3 ± 10.3
1,000 (4.4) 100 75.0 ± 10.8
10,000 (44) - 99.2 ± 0.3
a18 h exposure to DAC.
bMean values ± S.D., n ≥ 3.Page 3 of 10
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Effect of DAC concentration on DNA methylation and reactivation of p57 and p16 tumor suppressor genesFigure 1
Effect of DAC concentration on DNA methylation and reactivation of p57 and p16 tumor suppressor genes. 
A), HL-60 cells were treated with the indicated concentrations of DAC for 48 h. Total DNA was isolated at 72 h and the 
LINE-1 element gene methylation status was analyzed by COBRA assay. B), HL-60 cells were treated with the indicated con-
centrations of DAC for 48 h and total RNA was isolated at 72 h. Gene expression of 18 S ribosomal RNA gene and p57 were 
analyzed by RT-PCR. The amount of DNA amplified during the exponential phase of PCR was analyzed by quantification of 
amplified DNA by an Agilent 2100 Bioanalyzer. The control cells are HL-60 with no drug treatment. Control vs DAC 100 ng/
ml or 1,000 ng/ml p < 0.001. C), Calu-6 cells were treated with the indicated concentrations of DAC for 48 h. Total RNA was 
isolated at 72 h and 18 S ribosomal RNA gene and p16 gene expression analyzed by RT-PCR. The amount of DNA amplified 
during the exponential phase of PCR was analyzed by quantification of amplified DNA by an Agilent 2100 Bioanalyzer. For the 
quantitative detection of gene expression, we used 18S as the reference to normalize the data. The control cells were Calu-6 
with no drug treatment. Control vs DAC 100 ng/ml p < 0.01. Data are mean values ± S.D., n ≥ 3.
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(Qiagen). Genomic DNA was then treated with bisulfite
[8]. This bisulfite treatment converts unmethylated cyto-
sine residues to uracil, whereas 5-methylcytosine residues
remain unchanged.
Quantitation of DNA methylation by LINE assay
Analysis of changes in DNA methylation after DAC treat-
ment were evaluated by the method used for the LINE-1
assay [26]. PCR was performed on bisulfite treated DNA
using specific primers for either LINE-1 (sense 5'-TTA
GGG AGT GTT AGA TAG TGG-3' and antisense 5'-ATA
CCC TAC CCC CAA AAA TAA AAC-3' (primer sequences
were designed by Allen S. Yang, personal communica-
tion). The PCR conditions were the same as RT-PCR for
18S, except the annealing temperature was 53°C and the
total number of cycles was 35. The PCR products were
then purified using the DNA Clean and Concentrator Kit
(Zymo Research, CA, USA) and digested with Hinf I
enzyme (New Englend BioLabs, MA, USA) according to
manufacturer's protocols. Hinf I will only cut the repeti-
tive LINE-1 elements that were originally methylated,
leading to a 53 and a 398 bp fragmentation product that
can be quantified. The samples were placed on a 2% aga-
rose gel, detected by ethidium bromide staining and their
concentrations were evaluated by the Agilent 2100 Bioan-
alyzer.
Chemotherapy in mice
BALB/c × DBA/2 (hereafter called CD2F1) male mice 24–
28 g were obtained from Taconic Biotechnology (Ger-
mantown, NY, USA). The animal committee approved the
experimental protocols and the animals were handled in
accordance with institutional guidelines. Transplantation
of L1210 leukemic cells was performed by weekly i.p.
injections of 104 cells in 0.1 ml of RPMI-1640 medium
into CD2F1 mice. Seven days later, the ascitic fluid was
obtained and a cell count of the leukemic cells was per-
formed with a hemocytometer. For chemotherapy of
leukemia, the mice were injected i.v. with 0.1 ml of L1210
(104 cells) [6]. DAC was dissolved in PBS and sterilized by
0.2 µm filtration (Fig. 2). For i.v. infusion administration,
a Harvard infusion pump was used at a flow rate of 0.22
ml/h via a 25-gauge needle attached to a winged infusion
set into the lateral tail vein. Mice were placed in a
restrainer cage during drug treatment [8]. The survival
time of each group of leukemic mice was monitored and
the increase in life span (ILS) calculated (Fig. 2). Mice that
survived > 60 days after drug treatment were classified as
long-term survivors.
In vitro clonogenic assay of tumors after in vivo 
chemotherapy [27]
For the transplantation of EMT6 mammary tumor, the
tumor was removed by surgery and cut into small pieces
under sterile conditions. A tumor fragment of ~1 mm
diameter was injected s.c. Transplantations were per-
formed every two weeks. CD2F1 mice with EMT6 tumors
received DAC when the tumors reached a weight of ~200
mg (14 ± 2 days after s.c. injection of EMT6 cells). Mice
were administered the i.v. infusion of DAC at a flow rate
of 0.25 ml/h at 1.67 mg/kg/h for different infusion times
or a single 18 h i.v. infusion at different doses. Tumors
were then removed, cut and washed with medium. Cells
were trypsinized and filtered (37 µm) to remove tumor
fragments. The single cell suspension was centrifuged,
washed with medium and counted. Cells were then plated
in Petri dishes at a density of 500 and 1000 cells/dish and
14 days later, colonies were fixed, stained with Giemsa
and counted. The cloning efficiency was ~10%.
Pharmacokinetic analysis
Mice received DAC by i.v. infusion for 4 h to reach a
steady state concentration at the indicated rate of infusion
corresponding to different doses levels (Table 4). The
mice were anesthetized with carbon dioxide. At 1–2 min
post-infusion, blood samples were obtained by cardiac
puncture using a syringe flushed with heparin. The blood
samples were placed on ice and centrifuged at 10,000 × g
for 5 min. The supernatant was obtained and used for bio-
assay as described previously [22]. The bioassay measures
the growth inhibition of L1210 leukemic cells after 48 h
Effect of DAC on the survival time of mice with L1210 lym-phoid leukemiaFigure 2
Effect of DAC on the survival time of mice with 
L1210 lymphoid leukemia. CD2F1 mice received 1 × 104 
L1210 leukemic cells on day 1. Chemotherapy was started on 
day 2 with the indicated doses of DAC for 18 h i.v. infusion. 
The survival time of mouse was monitored. Control: n = 10 ; 
DAC 2.5 mg/kg : n = 10 ; DAC 5 mg/kg : n = 19 ; DAC 10 
mg/kg : n = 13 ; DAC 15 mg/kg : n = 12 ; DAC 20 mg/kg : n = 
3.Page 5 of 10
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to the medium and the growth inhibition determined.
The plasma concentration of DAC was estimated from the
standard curve (not shown) with known concentrations
of this analog. The experiment was repeated twice and per-
formed in duplicates.
Statistical considerations
For statistical analysis one-way ANOVA was performed.
The p-value was evaluated accordingly to Tukey's method
[28]. A value p < 0.05 was taken to indicate statistical sig-
nificance. The data represented the mean values ± S.D. for
n ≥ 3.
Results
Clonogenic assays were performed on human leukemic
and tumor cell lines to facilitate the translation of in vitro
data to the design of a protocol for a clinical trial. Human
HL-60 myeloid leukemic cells were exposed to different
concentrations of DAC for different exposure times (Table
1). DAC produced a loss of clonogenicity in a time- and a
dose-dependent manner. For a 24 h exposure, the concen-
tration that produced 50% loss of clonogenicity (IC50)
value was between 10 and 20 ng/ml (0.044 and 0.088
µM), whereas 200 ng/ml (0.88 µM) produced almost
100% in loss of clonogenicity.
Similarly, Calu-6 lung carcinoma cells were exposed to
different concentrations of DAC for different exposure
times (Table 2). DAC produced a loss of clonogenicity in
a dose- and a time-dependent manner. For the 4 and 8 h
exposure times, the IC50 value was in the range of 100 ng/
ml (0.44 µM). Compared to HL-60 leukemic cells, higher
concentrations and longer exposure times were required
to achieve a loss of clonogenicity of approximately > 90%.
In order to fully understand the antineoplastic activity of
DAC, we evaluated its epigenetic action at different con-
centrations on human leukemic and tumor cell lines. The
global DNA methylation status of HL-60 leukemic cells
was monitored by tracking the amount of methylated
LINE-1 element [26] (Fig. 1A). After a 48 h exposure, 100
ng/ml (0.44 µM) of DAC reduced the global methylation
status of HL-60 by 40% (p < 0.001, compared to untreated
cells), which seems to be sufficient to inhibit almost
100% of the clonogenic potential (Table 1). Lower con-
centration of DAC (10 ng/ml; 0.044 µM) did not produce
a significant loss in global DNA methylation (p > 0.05,
compared to untreated cells) in HL-60 cells. Similar
results were obtained from the examination of the tumor
suppressor gene p57, reported to be methylated in HL-60
cell lines [8]. HL-60 cells exposed to 100 ng/ml (0.44 µM)
for 48 h showed re-expression of p57 mRNA (Fig. 1B).
These data correlate well with the concentration required
to significantly decrease the promoter methylation of p57
as determined by the methylation-specific PCR assay [8]
(data not shown). When HL-60 cells are exposed to lower
concentrations of DAC (10 ng/ml; 0.044 µM), DNA
hypomethylation was not detected, even though that con-
centration could inhibit approximately 70% of the clono-
genicity of these cells (Table 1).
We next investigated the re-expression of p16 mRNA on
Calu-6 lung carcinoma cells exposed to different concen-
trations of DAC (Fig. 1C), because p16 has been reported
to be completely repressed by DNA methylation in these
cells [24]. The observed re-expression of p16 was found to
be time- and dose-dependent, with 100 ng/ml (0.44 µM)
required to achieve a significant re-expression at 24 h
(data not shown) and 48 h (Fig. 1C). These data corre-
lated well with the efficacy in reducing the clonogenic
potential of DAC, since both exposure times gave ~80%
loss of clonogenicity (Table 2).
The loss of clonogenicity was determined by the reduction
in colony formation after an 18 h drug exposure of the
L1210 murine lymphoid leukemic cells and of the EMT6
mammary tumor cells to different concentrations of DAC
(Table 3). The IC50 was ~15 ng/ml (0.066 µM) for L1210
and ~50 ng/ml (0.22 µM) for EMT6, according to calcula-
tions. In a previous study on L1210, we also observed that
shorter exposure times to DAC were less effective indicat-
ing a time-dependence [6,8]. DAC produced a loss of clo-
nogenicity in a dose-dependent manner in both cell lines,
although L1210 leukemic cells are much more sensitive
than the EMT6 cells. It is noteworthy that both murine
and human leukemic cells were more sensitive to the anti-
neoplastic action of 5-AZA-CdR than the solid tumor cells
of either species.
Table 4: Pharmacokinetics of DAC in mice.
Total dosea (mg/kg) Rate infusion (mg/kg/h) Plasma level ng/ml (µM)
5 0.278 80 ± 0.3b (0.35)
10 0.556 190 ± 0.5 (0.83)
20 1.11 610 ± 0.9 (2.68)
a18 h i.v. infusion of DAC. Blood sample was obtained at 4 h.
bMean values ± S.D., n ≥ 3.Page 6 of 10
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mic cells on day 1 and chemotherapy was started on day
2. The short plasma half-life of DAC in mice of 20–30 min
[29] supports the use of a continuous i.v. infusion for drug
administration. We administered different doses of DAC
ranging from 2.5 to 20 mg/kg (Fig. 2). The total dose of
2.5 mg/kg increased the survival time to 13.9 ± 1.3 days,
an 85% increase in life span as compared to untreated
mice which had a survival time of 7.5 ± 0.5 days. Dou-
bling the dose to 5 mg/kg produced an increase in survival
time to 26 days with 30% of the mice surviving more than
60 days, designated as long-term survivors in this model.
Increasing the dose of DAC to 10 and 15 mg/kg produced
a further increase in survival time and long-term survivors.
At a total dose of 20 mg/kg of DAC, 100% of treated mice
survived more than 60 days, indicating that they were all
long-term survivors as described in this model (Fig. 2).
The toxicity produced by the 20 mg/kg dose of DAC was
minimal as indicated by the < 3 % loss in body weight
(data not presented).
A very sensitive method to evaluate the antitumor activity
of DAC is to determine the cloning efficiency of tumor
cells in vitro after an in vivo treatment. This model is more
sensitive than measuring tumor volume because it is pos-
sible to detect 2 to 4 log cell kill. Mice were injected with
EMT6 mammary tumor cells s.c. and the treatment with
DAC was started when tumor reached a weight of approx-
imately 200 mg. In the initial experiments, the mice
received a constant rate of infusion of DAC (1.67 mg/kg/
h) for different infusion times (Fig. 3A). The tumors were
removed 48 h after treatment, the cells plated and colo-
nies were counted 14 days later. The loss of clonogenicity
of the tumor cells increased with the duration of the DAC
infusion. A complete loss of clonogenicity was observed
for the 24 h infusion at a total dose of 40 mg/kg of DAC.
However, this latter dose-schedule was very toxic to the
mice. In the second set of experiments, the mice received
a constant 18 h infusion of DAC at different total doses of
7.5, 15, 30 and 60 mg/kg (Fig. 3B). A reduction in the sur-
vival fraction of the tumor cells was dependent on the
dose of this analogue. DAC at a total dose of 30 mg/kg
produced an estimated ~2 log cell kill of the tumor cells
(Fig. 3B).
In a standard pharmacokinetic analysis, about 4 plasma
half-lives are required for a drug to reach steady state level
during a continuous i.v. infusion. The elimination half-
Effect of DAC therapy on mice on the survival of EMT6 mammary tumor cellsFigure 3
Effect of DAC therapy on mice on the survival of EMT6 mammary tumor cells. A), Mice received an i.v. infusion of 
DAC at 1.67 mg/kg/h for different duration (6, 12, 18 or 24 h) for total doses of 10, 20, 30 or 40 mg/kg, respectively. B), Mice 
received an 18 h i.v. infusion at different doses of DAC (7.5, 15, 30 or 60 mg/kg). CD2F1 mice were injected s.c. with EMT6 
tumor cells on day 1. DAC treatment as indicated was administered 14 days later. At 48 h post-treatment the tumors were 
removed and cells were plated in dishes for colony formation analysis. Each data point: n = 2. The cloning efficiency was about 
10%.Page 7 of 10
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[29]. For DAC it takes about 2 h to reach steady state level.
In order to determine plasma level of DAC in our leuke-
mic mouse model that produced 100% long-term survi-
vors, we obtained blood samples after 4 h infusion time
and estimated the level of this analogue using a bioassay.
When DAC was infused at a rate of 1.11 mg/kg/h, which
corresponds to the total dose of 20 mg/kg for 18 h infu-
sion, its estimated plasma level was 610 ng/ml (2.68 µM)
(Table 4).
Discussion
The silencing of TSGs by aberrant DNA methylation is a
frequent event in leukemogenesis and tumorigenesis.
Since this epigenetic event is reversible, it provides a very
interesting target for cancer therapy with DAC, a potent
and specific inhibitor of DNA methylation. Recently, DAC
was approved by the FDA for the treatment of the hema-
tological malignancy, myelodysplastic syndrome
[13,15,17]. However, even though some information is
available concerning the dose-scheduling of DAC, the
optimal dosing in humans is still not well defined. The
purpose of the present preclinical study was therefore to
better define the dose-schedule of DAC in order to pro-
vide data that may be useful to clinical investigators in
their effort to improve the efficacy of DAC therapy in
patients with cancer.
In this preclinical study we have investigated the in vitro
and in vivo antineoplastic activity of DAC on leukemic and
tumor cells. The objective of our study was to correlate the
in vitro concentrations of DAC that produced a significant
loss of clonogenicity with the doses that produce a potent
in vivo antineoplastic effect in mouse cancer models. Our
data clearly show that the in vitro loss of clonogenicity by
human and murine leukemic and tumor cells increase
with concentration of DAC. For HL-60 leukemic cells and
Calu-6 lung carcinoma cells the loss of clonogenicity at
the higher concentrations of DAC correlated with its
capacity to reactivate TSGs in these cell lines. In addition,
the inhibition of DNA methylation by DAC in the HL-60
leukemic cells also correlated with the loss of clonogenic-
ity. This latter result is in accord with our previous study
in mice with L1210 leukemia in which the chemothera-
peutic action of DAC was correlated with its inhibition of
DNA [7]. These observations further support the hypoth-
esis that the antineoplastic action of DAC is related to its
epigenetic action.
The antineoplastic action of DAC against both leukemic
and tumor cells also increased with the duration of treat-
ment. The longer exposure times allowed a greater frac-
tion of non-S phase cells to progress into S phase, where
DAC exerts its antineoplastic action [30]. Due to its S
phase specificity, the duration of DAC treatment is a very
important parameter that should be taken into considera-
tion in the design of trials with this epigenetic agent in
cancer patients.
In mice with L1210 leukemia, the antineoplastic activity
of DAC increased markedly with the dose. The estimated
steady-state plasma level of DAC was ~185 ng/ml (~0.8
µM) when administered at a total dose of 10 mg/kg as a
15-h i.v. infusion. This treatment produced ~50% long-
term survivors. The in vitro colony assay on L1210 leuke-
mic cells predicts a > 98% loss of clonogenicity with this
concentration, indicating a good correlation between the
in vitro and in vivo antileukemic action of DAC. The ques-
tion arises: Is it possible to translate the observations of
DAC in this mouse model of leukemia to the clinical treat-
ment of patients with leukemia? In this regard, it is inter-
esting to note that our data on cytosine arabinoside
(cytarabine, ARA-C) in the L1210 leukemia model in mice
[31] shows a good correlation with clinical studies on
intensive dose ARA-C in patients with acute myeloid
leukemia [32].
Although ARA-C and DAC are both deoxycytidine ana-
logues with identical metabolism and S phase specificity,
these agents have different mechanisms of action. One
major concern for clinical trials using DAC dose-intensifi-
cation is its hematopoietic toxicity. However, the hemat-
opoietic toxicity seen with post-remission high dose ARA-
C in leukemic patients is reversible [31]. Similarly, it
should be possible to investigate more intensive dose
therapy with DAC in patients with leukemia who have a
good performance status, since the pharmacology would
predict reversible toxicity with DAC as well [18].
The antineoplastic action of DAC against the EMT6 tumor
in mice also increased markedly with dose. In this model,
the tumor was excised after DAC treatment, and the cell
suspension obtained for the in vitro clonogenic assay. We
selected this model because it quantifies the survival of
tumor stem cells, which should be the key target of chem-
otherapy [33]. DAC at total dose of 15 mg/kg produced ~2
log reduction in clonogenic survival of EMT6 tumor cells.
The estimated plasma level of DAC during this infusion
was 200–400 ng/ml (0.88–1.76 µM). In patients with
solid tumors low dose DAC showed only minimal clinical
activity [20,21]. For example, DAC (60 to 90 mg/m2 total
dose) administered as a continuous 72 h i.v. infusion gave
steady state plasma levels in the range of 10 ng/ml (0.044
µM) [21]. In our pilot study on patients with advanced
lung cancer, we used intensive dose DAC (400 to 660 mg/
m2 as 8 h i.v. infusion) and observed some very promising
responses [22]. The mean steady-state DAC plasma level
in our study was estimated to be ~650 ng/ml (2.85 µM).
These preliminary clinical observations indicate that
higher plasma levels of DAC are required to obtain signif-Page 8 of 10
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our preclinical data. In addition, higher plasma levels of
DAC also have the potential to overcome the problem of
limited penetration of the anticancer drug into the tumor
as a possible cause of failure to respond to chemotherapy
[34]. The antitumor activity of DAC in patients undoubt-
ely merits further investigation in order to better refine the
dose-scheduling of this epigenetic agent in patients.
Conclusion
The in vitro assays indicate that the antineoplastic action
of DAC on leukemic and tumor cells increase markedly
with concentration. The in vivo antineoplastic action of
DAC against murine leukemia and tumor also increase
markedly with the dose. Pharmacokinetic analyses indi-
cate that the plasma concentration of DAC that produce a
potent in vivo antineoplastic effect is also very effective in
reducing the in vitro clonogenicity of leukemic and tumor
cells. These observations provide a strong rationale for
dose intensification in future clinical studies in order to
fully develop the chemotherapeutic potential of DAC in
patients with cancer [35-37]. Once a very effective dose
schedule for DAC is established, combination studies
with other gene reactivating drugs, such as histone
deacetylase inhibitors, are warranted [38-41].
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